Navigation Links
China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory
Date:12/15/2009

HARBIN, China, Dec. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has 30 medicines that will be included in the 2009 Edition of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory.

The 30 medicines treat a variety of common ailments and make up 17% of the Company's revenues for the first nine months of 2009. Nine of the medicines, including Salbutamol, Compound Sulfamethoxazole Tablets, Nitrofurantoin Enteric-coated Tablets, Amidopyrine and Phenacetin Compound Tablets, Isatis Root Granules, Pulse-activating Decoction, Compound Salvia Tablets, Guanxinsuhe Capsules, and Antibiotic and Liver Cholaneresis Soothing Tablets, are Category A medicines. Consumption of Category A drugs will be fully reimbursed by the national basic medical insurance system.

The 2009 Edition Directory includes a total of 2,151 medicines. There are 1,164 Western drugs in the Directory, including 349 Category A medicines, 791 Category B medicines, 20 restricted work injury insurance agents, and four maternity insurance agents. In addition, there are 987 Chinese medicines, including 154 Category A medicines and 833 Category B medicines.

"We are excited to have 30 medicines included in the 2009 Edition Directory, which we expect to result in increased sales volumes for these products as pharmacies in China make them widely available to meet demand from patients," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Few other pharmaceutical companies in China have accomplished this goal, and it further demonstrates the market potential for our rich product portfolio."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the inclusion of the Company's drugs in the 2009 Edition of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Medicine Directory. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-5399-4069
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Biologic Products to Ring NASDAQ Opening Bell
2. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
3. Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit
4. Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies
5. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
6. China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List
7. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
8. China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information
9. Niusule Expands Geographic Footprint in China
10. China Pharma Holdings, Inc. to Present at Brean Murray China Growth Conference
11. China Business Knowledge Launches “China Prospects Forum” -- Dec. 9, 2009, New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, ... could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma ... read it now. , Biomarkers are components in the blood, tissue or ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):